Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: No enemy but time?

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 4, 2015, Pages 453-456

  Pafili, Kalliopi ^a   Papanas, Nikolaos ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Diabetes mellitus; Luseogliflozin; Oral hypoglycaemic agents; Sodium glucose transport inhibitors; Therapy.

Indexed keywords

LUSEOGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; 1,5-ANHYDRO-1-(5-(4-ETHOXYBENZYL)-2-METHOXY-4-METHYLPHENYL)-1-THIOGLUCITOL; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; SODIUM GLUCOSE COTRANSPORTER 2; SORBITOL;

ADD ON THERAPY; BODY WEIGHT; COST EFFECTIVENESS ANALYSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM;

BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2; SORBITOL;

EID: 84922933951     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.994505     Document Type: Review

References (15)

1. Papaspyros NS. The history of diabetes mellitus. 2nd edition. Stuttgart, Thieme, Stuttgart, Germany; 1964
2. Dobson M. Experiments and observations on the urine in diabetes. Med Obs Inq 1776;5:298-316
3. Bergman HC, Drury DR. The relationship of kidney function to the glucose utilization of the extra abdominal tissues. Am J Physiol 1938;124:279-84
4. Gerich JE. Physiology of glucose homeostasis. Diabetes Obes Metab 2000;2(6):345-50
5. Moe OW, Wright SH, Palacin M. Renal handling of organic solutes. In: Brenner BM, Rector FC, editors. Brenner & Rector's the kidney. Volume I 8th edition. Saunders Elsevier; Philadelphia PA: 2008. p. 214-47
6. Ganong WF. Renal function and mixturition. In: Review of medical physiology. 21st editon. Lange Medical Books/McGraw Hill; New York, NY: 2003. p. 702-32
7. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Int Med 2007;261(1):32-43
8. Pafili K, Papanas N. Tofogliflozin: the road goes ever on. Expert Opin Pharmacother 2014;15(9):1197-201
9. Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis 2009;53(5):875-83
10. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013;159(4):262-74
11. Berhan A, Barker A. Sodium glucose cotransport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials. BMC Endocr Disord 2013;13:58
12. Musso G, Gambino R, Cassader M, et al. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012;44(4):375-93
13. Katsiki N, Papanas N, Mikhailidis DP. Dapagliflozin: more than just another oral glucose-lowering agent?. Expert Opin Investig Drugs 2010;19(12):1581-9
14. Seino Y. Luseogliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother 2014;15(18):2741-9
15. Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005;54(12):3427-34